1. Stakhovskyi1, A. Tymoshenko1,2, V. Chekhun2

1National Cancer Institute of Ukraine
2R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine


Summary. Aim: to determine the quality of life, progression-free (PFS) and overall survival (OS) of patients with localized prostate cancer (PC) with existing metabolic syndrome (MS) and the development of bone metastases (BM) after radical prostatectomy (RP). Objects and methods: а retrospective clinical study diagnosed in 35 patients with localized PC and development of BM. Patients with a moderate (Grade group 2.3) and high (Grade group 4.5) risk of disease progression are divided into subgroups based on the presence and absence of MS. Analyzed indicators of recurrence-free and overall survival; the quality of life of patients was assessed using the QLQ-C30 questionnaire. Results: among 35 study participants after RP with the development of BM – 27 (77.1%) have MS, 8 (22.9%) haven’t features of MS. MS was found in 25.9% of patients with GG 2.3 and 74.1% of GG 4.5; the absence of MS was observed in 62.5 and 37.5% of patients, respectively. The median progression-free survival of patients with РС GG 2.3 and existing MS was 13.3% lower compared to the rate of patients without MS; in patients with PС GG 4.5 – by 10.5%. They also noted a decrease in the median overall survival of patients with MS compared to the rate of patients without MS by 6.4 (GG 2.3) and by 23.9% (GG 4.5). The data of the study demonstrate a decrease in the general health status of patients before RP and at the time of development of BM with existing MS by 27.6%, without MS by 5.5%. Decrease in quality-of-life indicators was noted in the following indicators: social status, fatigue, lack of appetite and the presence of financial difficulties. Conclusion: the investigation analysis showed that presence of metabolic syndrome influence on decreasing quality of life, progression-free survival and overall survival rates in patients with prostate cancer.

Keywords: prostate cancer, metabolic syndrome, bone metastases, survival, quality of life



  1. Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71 (3): 209–49. doi: 3322/caac.21660.
  2. Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 2020; 77 (1): 38–52. doi: 1016/j.eururo.2019.08.005.
  3. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394–424. doi: 10.3322/caac.21492.
  4. Stakhovsky EO, Tymoshenko AV, Voilenko OA, et al. Metabolic syndrome as a factor of prostate cancer progression. Oncology 2021; 23 (3): 144–8. doi: 32471/oncology.2663-7928.t-23-3-2021-g.9577. (in Ukrainian)
  5. Tymoshenko AV. Peculiarities of the impact of metabolic syndrome on the aggressiveness of the course of prostate cancer. Clin Oncol 2023; 13 (2): 1–4. doi: 32471/clinicaloncology.2663-466X.50-2.30779 (in Ukrainian)
  6. Norgaard M, Jensen AO, Jacobsen JB, et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010; 184 (1): 162– doi: 10.1016/j.juro.2010.03.034.
  7. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12 (20 Pt 2): 6243s-6249s. doi: 10.1158/1078-0432.CCR-06-0931.
  8. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011; 8 (6): 357– doi: 10.1038/nrclinonc.2011.67.
  9. Courtney PT, Deka R, Kotha NV, et al. Metastasis and mortality in men with low- and intermediate-risk prostate cancer on active surveillance. J Natl Compr Canc Netw 2022; 20 (2): 151–9. doi: 10.6004/jnccn.2021.7065.
  10. Baldessari C, Pipitone S, Molinaro E, et al. Bone metastases and health in prostate cancer: from pathophysiology to clinical implications. Cancers (Basel) 2023; 15 (5): 1518. doi: 10.3390/cancers15051518.
  11. Eymech O, Brunckhorst O, Deacon M, et al. The impact of radical prostatectomy on the social well-being of prostate cancer survivors: A qualitative meta-synthesis. Eur J Cancer Care 2022; 31 (4): doi: 10.1111/ecc.13630.
  12. Skwirczyńska E, Wróblewski O, Tejchman K, et al. Prostate cancer eligible for radical prostatectomy: self-esteem of patients and forms of coping with stress. Int J Environ Res Public Health 2022; 19 (11): 6928. doi: 10.3390/ijerph19116928.
  13. Van der Poel HG, Tillier C, de Blok WM, et al. Interview-based versus questionnaire-based quality of life outcomes before and after prostatectomy. J Endourol 2013; 27 (11): 1411–16. doi: 10.1089/end.2012.0735.
  14. Tymoshenko A, Med V, Voylenko O, et al. Clinical and morphological features of bone metastases diagnosis in patients with prostate cancer. Oncology 2023; 25 (1): 63– doi: 10.15407/oncology.2023.01.063. (in Ukrainian)

No comments » Add comment